Additionally, an antibody against FRβ could be used to improve the treatment of solid tumors such as ovarian cancer by eliminating immunosuppressive, pro-tumorigenic M2 macrophages in the microenvironment. Here, FOLR2 is linked to ovarian carcinoma.